Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
A future study linking tumor genetics with CLL dynamics
Monoclonal antibodies: the future of MM treatment?
CONTI-PV: a 2-year follow-up of interferon product AOP2014
An introduction to the HOVON-141 trial in patients with CLL